61 patents
Page 3 of 4
Utility
Ophthalmic composition for treating dry eye and symptoms thereof
30 Sep 20
It is provided an ophthalmic composition, particularly formulated as eye drops, comprising a non-ionic surfactant as active ingredient, wherein the non-ionic surfactant is present in an effective amount from 0.01 to 8 weight/volume % based on the total composition, for use in treating or preventing dry eye and/or for relieving one or more symptoms and/or signs of dry eye.
Francisco Javier Galan Valdivia
Filed: 5 Mar 20
Utility
Combination Therapy
2 Sep 20
Described herein are compounds and compositions for treating glaucoma and/or reducing intraocular pressure.
Casey Kopczynski, Cheng-Wen Lin, Jill Marie Sturdivant, Mitchell A. deLong
Filed: 2 Feb 20
Utility
Compounds, Compositions and Methods for Treatment of Myopia
5 Aug 20
Provided herein are 8-methyl-8-azabicyclo[3.2.1]octan-3-yl and pyridin-4-ylmethanyl ester and amide compounds and compositions.
Eric Carlson, Mitchell A. deLong
Filed: 30 Jan 20
Utility
Intravitreal Drug Delivery Systems for the Treatment of Ocular Conditions
22 Jul 20
The disclosure teaches precisely engineered biodegradable drug delivery systems and methods of making and utilizing such systems.
Stuart Williams, Sanjib Kumar Das, Tomas Navratil, Melissa Sandahl, Janet Tully, Rozemarijn Verhoeven
Filed: 11 Dec 19
Utility
Beta- and Gamma-amino-isoquinoline Amide Compounds and Substituted Benzamide Compounds
15 Jul 20
Disclosed are beta and gamma-amino isoquinoline amide compounds and substituted benzamide compounds.
Mitchell A. deLong, Jill Marie Sturdivant, Susan M. Royalty
Filed: 11 Dec 19
Utility
6-AMINOISOQUINOLINE Compounds
10 Jun 20
6-Amino isoquinoline compounds are provided that influence, inhibit or reduce the action of a kinase.
Mitchell A. deLong, Susan M. Royalty, Jill Marie Sturdivant, Geoffrey Richard Heintzelman
Filed: 10 Nov 19
Utility
Dual mechanism inhibitors for the treatment of disease
18 May 20
Provided are compounds that are inhibitors of both rho kinase and of a monoamine transporter (MAT) act to improve the disease state or condition.
Mitchell A. deLong, Jill Marie Sturdivant, Susan M. Royalty
Filed: 6 Jun 19
Utility
Beta- and Gamma-amino-isoquinoline Amide Compounds and Substituted Benzamide Compounds
6 May 20
Disclosed are beta and gamma-amino isoquinoline amide compounds and substituted benzamide compounds.
Mitchell A. deLong, Jill Marie Sturdivant, Susan M. Royalty
Filed: 29 Dec 19
Utility
Dual Mechanism Inhibitors for the Treatment of Disease
29 Apr 20
Provided are compounds that are inhibitors of both rho kinase and of a monoamine transporter (MAT) act to improve the disease state or condition.
Mitchell A. deLong, Jill Marie Sturdivant, Susan M. Royalty
Filed: 29 Dec 19
Utility
Combination Therapy
29 Apr 20
Described herein are compounds and compositions for treating glaucoma and/or reducing intraocular pressure.
Casey Kopczynski, Cheng-Wen Lin, Jill Marie Sturdivant, Mitchell A. deLong
Filed: 29 Dec 19
Utility
Rho kinase inhibitors
20 Apr 20
Disclosed are novel substituted 2H-isoquinolin-1-one and 3H-quinazolin-4-one derivatives useful as inhibitors of Rho kinase and for treating a variety of diseases and disorders that are mediated or sustained through the activity of Rho kinase, including cardiovascular diseases, pharmaceutical compositions comprising such compounds, methods for using such compounds and processes for making such compounds.
Todd Bosanac, John David Ginn, Eugene Richard Hickey, Thomas Martin Kirrane, Jr., Weimin Liu, Anthony S. Prokopowicz, Sabine K. Schlyer, Cheng-Kon Shih, Roger John Snow, Michael Robert Turner, Frank Wu, Erick Richard Young
Filed: 28 Dec 17
Utility
Intravitreal drug delivery systems for the treatment of ocular conditions
20 Apr 20
The disclosure teaches precisely engineered biodegradable drug delivery systems and methods of making and utilizing such systems.
Stuart Williams, Sanjib Kumar Das, Tomas Navratil, Melissa Sandahl, Janet Tully, Rozemarijn Verhoeven
Filed: 21 Jul 16
Utility
Aryl Cyclopropyl-amino-isoquinolinyl Amide Compounds
1 Apr 20
Provided herein are amino isoquinolinyl amide and sulfonamide compounds that affect the function of kinases and other proteins in a cell and that are useful as therapeutic agents.
Mitchell A. deLong, Jill M. Sturdivant, Cynthia L. Lichorowic, Andriy Kornilov
Filed: 12 Sep 19
Utility
Combination therapy
16 Mar 20
Described herein are compounds and compositions for treating glaucoma and/or reducing intraocular pressure.
Casey Kopczynski, Cheng-Wen Lin, Jill Marie Sturdivant, Mitchell A. deLong
Filed: 2 May 18
Utility
Isoquinoline-steroid Conjugates and Uses Thereof
4 Mar 20
Provided herein are compounds and pharmaceutical compositions useful in modulating kinase activity, and related diseases.
Mitchell A. deLong, Eric Carlson, Casey Kopczynski, Jill M. Sturdivant, Cynthia Lichorowic
Filed: 29 Aug 19
Utility
Combination therapy
24 Feb 20
Described herein are compounds and compositions for treating glaucoma and/or reducing intraocular pressure.
Casey Kopczynski, Cheng-Wen Lin, Jill Marie Sturdivant, Mitchell A. deLong
Filed: 20 Feb 18
Utility
Process for the preparation of kinase inhibitors and intermediates thereof
3 Feb 20
Described are processes for the synthesis of certain compounds, useful for treating diseases, e.g. eye disease, such as glaucoma and ocular hypertension, in a subject.
Jill Marie Sturdivant, Mitchell A. deLong, Gilles Chambournier, Michael G. Pamment, Victor Fedij
Filed: 16 Nov 15
Utility
Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds
13 Jan 20
Disclosed are beta and gamma-amino isoquinoline amide compounds and substituted benzamide compounds.
Mitchell A. deLong, Jill Marie Sturdivant, Susan M. Royalty
Filed: 20 Sep 18
Utility
Dual Mechanism Inhibitors for the Treatment of Disease
1 Jan 20
Provided are compounds that are inhibitors of both rho kinase and of a monoamine transporter (MAT) act to improve the disease state or condition.
Mitchell A. deLong, Jill Marie Sturdivant, Susan M. Royalty
Filed: 6 Jun 19
Utility
6-aminoisoquinoline compounds
11 Nov 19
6-Amino isoquinoline compounds are provided that influence, inhibit or reduce the action of a kinase.
Mitchell A. deLong, Susan M. Royalty, Jill Marie Sturdivant, Geoffrey Richard Heintzelman
Filed: 28 Dec 17